Monitor emerging drug resistance
in real time
Malaria speciation and drug resistance
screening in minutes, sample to result
Resistance to anti-malaria drugs
is spreading
Accurate results in minutes
in the hospital, clinic or field
Placing gold standard testing into the
hands of frontline healthworkers
Every minute a child dies of malaria
Every minute a child dies of malaria
One Device, Endless Possibilities™
Q-POC™: The Handheld Laboratory

The NANOMAL PROJECT

The Future of malaria diagnosis

Our FP7 European Union funded NanoMal Consortium is developing a handheld laboratory that will deliver complex malaria diagnostics in minutes for a few dollars in any setting across the globe.

Making malaria elimination possible

Our handheld laboratory will provide frontline healthworkers with the definitive tool to diagnose,
manage and monitor malaria and drug resistance.

  • Results in 10-15 minutes
  • Malaria diagnosis & drug resistance testing
  • Directs right first time prescribing
  • Handheld, user friendly, low cost
  • Mobile data connection

The Nanomal Consortium partners are: 
St George's University London | QuantuMDx Group | The Karolinska Insititute | Tubingen University.

St Georges University London is a pertner in the Nanomal ProjectQuantuMDx are partners in the Nanomal ProjectKarolinska Partners for the Nanomal ProjectTubingen University is a pertner in the Nanomal Project

 

CEO Elaine Warburton receives an OBE for services to health innovation

The Nanomal ProjectNorthGene Limited, one of the UK's first commercial DNA testing companies has received notification from the Ministry of Justice that their laboratory is now accredited to carry out scientific tests for parentage where the court gives a 'Section 20 direction'. NorthGene recently achieved UKAS accreditation for ISO 17025 allowing them to perform legal DNA tests.

Read more >

CEO Elaine Warburton receives an OBE for services to health innovation

The Nanomal Project QMDx are delighted to announce our CEO Elaine Warburton receives an OBE for services to health innovation!

QuantuMDx awarded £1m grant to develop rapid multi-drug resistant TB test for their smartphone-like device

The Nanomal Project British biotech QuantuMDx has been awarded a UK government's Technology Strategy Board (TSB) grant to develop Q-TB™, a rapid and cheap test that will analyse sputum samples at the patient's side and diagnose multi-drug resistant TB (MDR-TB) within 15 minutes enabling immediate personalised prescription of the most effective TB drug treatment. TB causes 2m deaths every year despite most cases being curable. The disposable Q-TB™ cartridge will be used on Q-POC™, QuantuMDx's universal handheld diagnostic device and provide a technology leap for both developing nations which lack healthcare infrastructure and the overburdened healthcare systems of developed nations which are seeing an re-emergence of MDR-TB, particularly within inner cities.

Read more >